Stark David Matthew
Known title: Exec. VP Chief Legal OfficerCIK: 0001722360
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▼ Sell | Open Market | 49,475 | $466K | 3/7/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 16,491 | $164K | 3/6/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 20,199 | — | 3/5/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 13,931 | — | 3/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 31,836 | — | 3/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 18,430 | — | 2/28/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 18,430 | $182K | 2/28/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 44,953 | — | 2/28/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 44,953 | $444K | 2/28/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 58,163 | $526K | 7/28/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 9,057 | $67K | 3/7/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 20,199 | — | 3/5/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 37,939 | — | 3/4/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 17,008 | $127K | 3/4/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 13,930 | — | 3/4/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 6,246 | $47K | 3/4/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 18,430 | — | 2/28/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 6,452 | $53K | 2/28/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 12,538 | — | 2/9/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 6,110 | $55K | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.